Effectiveness and Safety of Secukinumab in 608 Patients with Psoriatic Arthritis in Real Life: a 24-month Prospective, Multicentre Study

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2021 Feb 17

PMID 33593933

Citations 23

Authors

Roberta Ramonda

Mariagrazia Lorenzin

Antonio Carriero

Maria Sole Chimenti

Raffaele Scarpa

Antonio Marchesoni

Ennio Lubrano di Scorpaniello

Carlo Salvarani

Alberto Cauli

Angelo Semeraro

Leonardo Santo

Augusta Ortolan

Andrea Doria

Elena Fracassi

Giulia Virelli

Marco Masia

Rosalinda Fanizzi

Elisa Visalli

Giorgio Amato

Antonio Carletto

Rosario Foti

Affiliations

Soon will be listed here.

Abstract

Objectives: To evaluate in a multicentric Italian cohort of patients with psoriatic arthritis (PsA) on secukinumab followed for 24 months: (1) the long-term effectiveness and safety of secukinumab, (2) the drug retention rate and minimal disease activity (MDA), (3) diﬀerences in the outcomes according to the biological treatment line: biologic-naïve patients () versus multifailure () patients.

Methods: Consecutive patients with PsA receiving secukinumab were evaluated prospectively. Disease characteristics, previous/ongoing treatments, comorbidities and follow-up duration were collected. Disease activity/functional/clinimetric scores and biochemical values were recorded at baseline (T0), 6(T6), 12(T12) and 24(T24) months. Effectiveness was evaluated overtime with descriptive statistics; multivariate Cox and logistic regression models were used to evaluate predictors of drug-discontinuation and MDA at T6. Infections and adverse events were recorded.

Results: 608 patients (41.28% men; mean (SD) age 52.78 (11.33)) were enrolled; secukinumab was prescribed as first-line biological treatment in 227 (37.34%) patients, as second (or more)-line biological treatment in 381 (62.66%). Effectiveness of secukinumab was shown with an improvement in several outcomes, such as Ankylosing Spondylitis Disease Activity Score (T0=3.26 (0.88) vs T24=1.60 (0.69) ;p=0.02) and Disease Activity Index for Psoriatic Arthritis (T0=25.29 (11.14) vs T24=7.69 (4.51); p<0.01). At T24, showed lower Psoriasis Area Severity Index (p=0.04), erythrocyte sedimentation rate and C reactive protein (p=0.03 ;p=0.05) and joint count (p=0.03) compared with . At T24, MDA was achieved in 75.71% of and 70.37% of . Treatment was discontinued in 123 (20.23%) patients, mainly due to primary/secondary loss of effectiveness, and in 22 due to adverse events. Retention rate at T24 was 71% in the whole population, with some difference depending on secukinumab dosage (p=0.004) and gender (p=0.05).

Conclusions: In a real-life clinical setting, secukimumab proved safe and effective in all PsA domains, with notable drug retention rate.

Citing Articles

Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry.

Lopalco G, Morrone M, Atzeni F, Bazzani C, Bianchi F, Cantatore F Ther Adv Musculoskelet Dis. 2025; 17:1759720X251315138.

PMID: 39897378 PMC: 11783553. DOI: 10.1177/1759720X251315138.

Cycling versus swapping strategies with TNF-α inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice.

Lumetti F, Ariani A, Marchesoni A, Becciolini A, Giuggioli D, Sandri G Sci Rep. 2024; 14(1):24922.

PMID: 39438513 PMC: 11496729. DOI: 10.1038/s41598-024-75190-x.

Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence.

Malagoli P, Dapavo P, Amerio P, Atzori L, Balato A, Bardazzi F Dermatol Ther (Heidelb). 2024; 14(10):2739-2757.

PMID: 39316358 PMC: 11480300. DOI: 10.1007/s13555-024-01255-4.

Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.

Ritchlin C, Mease P, Boehncke W, Tesser J, Chakravarty S, Rampakakis E Clin Rheumatol. 2024; 43(8):2551-2563.

PMID: 38844682 PMC: 11269379. DOI: 10.1007/s10067-024-06991-8.

Clinical Features and Disease Activity in Psoriatic Arthritis: A Sex-Related Perspective on Leptin and Comorbidity.

Toledano E, Gomez-Lechon L, Chacon C, Hidalgo C, Ibanez M, Marquez A J Clin Med. 2024; 13(10).

PMID: 38792501 PMC: 11121807. DOI: 10.3390/jcm13102959.

References

Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A . Body weight, gender and response to TNF-α blockers in axial spondyloarthritis. Rheumatology (Oxford). 2014; 53(5):875-81. DOI: 10.1093/rheumatology/ket433. View

Boutet M, Nerviani A, Gallo Afflitto G, Pitzalis C . Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci. 2018; 19(2). PMC: 5855752. DOI: 10.3390/ijms19020530. View

McInnes I, Mease P, Kirkham B, Kavanaugh A, Ritchlin C, Rahman P . Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386(9999):1137-46. DOI: 10.1016/S0140-6736(15)61134-5. View

Magrey M, Bozyczko M, Wolin D, Mordin M, McLeod L, Davenport E . Evaluation of the Feasibility of a Web-Based Survey to Assess Patient-Reported Symptom Improvement and Treatment Satisfaction Among Patients with Psoriatic Arthritis Receiving Secukinumab. Clin Drug Investig. 2019; 39(12):1205-1212. PMC: 6842331. DOI: 10.1007/s40261-019-00856-8. View

Coates L, Mease P, Gossec L, Kirkham B, Sherif B, Gaillez C . Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study. Arthritis Care Res (Hoboken). 2018; 70(10):1529-1535. DOI: 10.1002/acr.23537. View

Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, DAngelo S . Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2020; 80(5):582-590. PMC: 8053347. DOI: 10.1136/annrheumdis-2020-218808. View

Coates L, Kavanaugh A, Mease P, Soriano E, Acosta-Felquer M, Armstrong A . Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016; 68(5):1060-71. DOI: 10.1002/art.39573. View

Coates L, Helliwell P . Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken). 2010; 62(7):965-9. DOI: 10.1002/acr.20155. View

Bissonnette R, Luger T, Thaci D, Toth D, Lacombe A, Xia S . Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018; 32(9):1507-1514. PMC: 6175198. DOI: 10.1111/jdv.14878. View

10.

Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M . EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020; 79(6):700-712. PMC: 7286048. DOI: 10.1136/annrheumdis-2020-217159. View

11.

Scrivo R, Giardino A, Salvarani C, Foti R, Afeltra A, Viapiana O . An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. Clin Exp Rheumatol. 2019; 38(1):107-114. View

12.

Michelsen B, Ornbjerg L, Kvien T, Pavelka K, Nissen M, Nordstrom D . Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis. Rheumatology (Oxford). 2020; 59(9):2455-2461. DOI: 10.1093/rheumatology/kez656. View

13.

Sherlock J, Joyce-Shaikh B, Turner S, Chao C, Sathe M, Grein J . IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012; 18(7):1069-76. DOI: 10.1038/nm.2817. View

14.

Schreiber S, Colombel J, Feagan B, Reich K, Deodhar A, McInnes I . Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019; 78(4):473-479. PMC: 6530077. DOI: 10.1136/annrheumdis-2018-214273. View

15.

Orbai A, de Wit M, Mease P, Shea J, Gossec L, Leung Y . International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2016; 76(4):673-680. PMC: 5344772. DOI: 10.1136/annrheumdis-2016-210242. View

16.

Klavdianou K, Lazarini A, Grivas A, Tseronis D, Tsalapaki C, Rapsomaniki P . Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis. Front Med (Lausanne). 2020; 7:288. PMC: 7317305. DOI: 10.3389/fmed.2020.00288. View

17.

Pinto Tasende J, Maceiras Pan F, Mosquera Martinez J, Fernandez Dominguez L, Correa Rey B, Garcia Porrua C . Secukinumab as Biological Treatment for Psoriatic Arthritis in Real Clinical Practice. Reumatol Clin (Engl Ed). 2019; 17(4):203-206. DOI: 10.1016/j.reuma.2019.07.002. View

18.

Marchesoni A, Olivieri I, Salvarani C, Pipitone N, DAngelo S, Mathieu A . Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exp Rheumatol. 2017; 35(6):991-1010. View

19.

Egeberg A, Bryld L, Skov L . Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019; 81(1):173-178. DOI: 10.1016/j.jaad.2019.03.048. View

20.

Orbai A, McInnes I, Coates L, Husni M, Gladman D, Gossec L . Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. J Rheumatol. 2019; 47(6):854-864. DOI: 10.3899/jrheum.190507. View